Kate Winslet, a veteran actress known for her exceptional performances, secured nominations in two distinct categories. Her portrayal of a complex character in the critically acclaimed drama series "Mare of Easttown" earned her a spot in the Best Actress in a Television Series category. Additionally, Winslet's outstanding work in the heartfelt film "Ammonite" landed her a nomination for Best Actress in a Motion Picture - Drama. With her unmatched talent and versatility, Winslet continues to captivate audiences and critics alike, solidifying her status as a powerhouse in the industry.In the midst of the backlash, the director of the play, renowned playwright Sarah Loomis, issued a statement defending the production and insisting that artistic freedom should not be stifled by censorship. However, her words only seemed to further enrage the critics, who accused her of being out of touch with the concerns of the public.
In the face of overwhelming odds, the Syrian-Chinese community remains steadfast in their determination to survive and build a better future for themselves and their families. Their courage and resilience in the face of adversity stand as a testament to the indomitable human spirit and the power of hope in the darkest of times.
S.Korea political upheaval shows global democracy's fragility - and resilienceIn recent days, gold prices have been experiencing a decline, with many investors shifting their focus to other assets in response to a more optimistic economic outlook. This shift in sentiment has led to a decrease in demand for gold, causing prices to trend lower.
Ministers are forging ahead with plans to use electric vehicles (EVs) for combat on the battlefield despite warnings from military grandees that they could put Armed Forces at risk. The Telegraph has learnt that the Ministry of Defence will be ramping up testing of s next year at the Army’s Bovington Garrison in Dorset, home of the . The testing, described by an insider as “putting these vehicles through their paces”, is at an experimental phase, but is an expansion of plans first mooted under the Conservative government on the development of combat EVs. Since coming to office in July, the Government has handed more than £400,000 in contracts to Magtec, a defence firm that specialises in the electrification of vehicles. In October, John Healey, the Defence Secretary, visited the firm’s design and manufacturing facility in south Yorkshire, saying he was impressed with the company’s “creative flair to improve the battlefield performance and the environmental performance of military vehicles”. The Government has pledged to put its wider at the heart of its defence industrial strategy, which was launched alongside a speech by Sir Keir Starmer this week on a major reset of government policy. It said the strategy would “support net zero, regional growth, and economic security and resilience”. A government source added: “New and emerging technologies can support decarbonisation efforts and improve battlefield capability, reducing the supply chain vulnerability of liquid fuel and also reducing the heat signature and noise of vehicles on the battlefield.” Asked about the possibility of an electric tank, they added: “never say never”. However, military grandees on Saturday night called for the Government to think again before pressing ahead with the “crazy endeavour”, warning that a rush to net zero on the battlefield could put British troops at a disadvantage. , former commander of the British forces in Afghanistan, said: “What this amounts to is virtue signalling by MOD, trying to get into the climate change agenda. I suspect it will be wasting quite a lot of people’s time and resources in trying to show they are playing their part. At the moment the technology is just not there. “It is hard enough to keep the current vehicles supplied with fuel, that is a massive operation on its own - I just can’t see how it would possibly work with EVs. “Fighting battles in an extremely difficult activity - to make it unnecessarily even more difficult seems to be a crazy endeavour. “I would be pretty confident that it is just not at all a starter in terms of maintaining the level of battleground capability that we have now.” of Spithead, former First Sea Lord, said: “The aim must be to get war-winning equipment that we can use in the conditions we find ourselves fighting in; that enable us to fight, win and defeat enemies like Russia. That should be the aim of what we are developing. “If they are saying we should have things that will achieve net zero, I don’t think that is the priority. We need things that we can use to fight and win - because we may well be at war in the next few years. “I have a horrible feeling some people might be thinking net zero is so important, but that is not the important thing in warfare terms.” , commander of the Royal Irish during the invasion of Iraq, said: “I doubt our adversaries will be looking much at this sort of thing. They’ll be looking for immediate effect, not approval ratings or whatever. “I doubt a battery can currently provide the horsepower necessary for warfare. What’s driving this? Is it battlefield necessity or fashion? If it’s fashion then it’s a bad idea. Renewables alone aren’t sufficient to deliver the power we need for potential conflicts.” Ed Arnold, senior research fellow at the Royal United Services Institute, said: “The greening of the military needs to be communicated very well. It can’t just be an abstract net zero target. They have to show it will improve British defence capabilities. You have to make the argument for tactical advantage at the soldier level.” In 2019 , then Chief of the General Staff, said the current fleet of military vehicles would be the last to rely on fossil fuels. At the time the MoD announced a £3.2million project to develop green combat vehicles that would reduce the force’s carbon footprint. Brigadier James Vigne, the army’s head of climate change and sustainability, has previously said: “My personal view is that the internal combustion engine is on its last legs and we could see a switch to new technologies quickly.” In a 2022 paper on future electrification of vehicles, the Army said the effort was a “win-win” which “enables operational advantage, reduces logistic demand, and puts the Army on the path to meeting net zero”. The MoD has previously pledged to electrify its fleet of support vehicles in the UK by 2027. In 2023, specially converted Land Rovers went through rigorous testing at Millbrook, a proving ground in Bedfordshire, with the trial wrapping up earlier this year. Work has been underway on the electrification of and , two of the Army’s key armoured patrol vehicles. A Ministry of Defence spokesman said: “The rapid advancement of electric vehicle technology has opened up new possibilities for military applications, with comprehensive trials in 2025 set to explore whether EVs can match or exceed the performance of conventional vehicles across battlefield operations. “The Ministry of Defence remains committed to pursuing innovations that could enhance the operational effectiveness of our Armed Forces, while also supporting sustainability where possible.”
The right book can inspire the young readers in your life, from picture books to YA novels
WOONSOCKET, R.I. , Dec. 16, 2024 /PRNewswire/ -- CVS Health Corporation ("CVS Health" or the "Company," NYSE: CVS) announced today the applicable Reference Yields and Total Consideration (each as summarized in the tables below) to be paid in connection with the previously announced cash tender offer (the "Maximum Tender Offer" ) for the maximum principal amount of the following series of Maximum Tender Offer Notes (as defined below) for which the aggregate purchase price, not including Accrued Interest (as defined below), payable in respect of such Maximum Tender Offer Notes, does not exceed $1,774,423,242.62 (such maximum purchase price, the "Maximum Tender Offer Amount"): its 2.700% Senior Notes due 2040, the 3.875% Senior Notes due 2047 issued by its wholly-owned subsidiary Aetna Inc. ("Aetna"), its 4.250% Senior Notes due 2050, the 4.125% Senior Notes due 2042 issued by Aetna, its 4.125% Senior Notes due 2040, its 2.125% Senior Notes due 2031, its 1.875% Senior Notes due 2031, its 5.050% Senior Notes due 2048, the 4.500% Senior Notes due 2042 issued by Aetna and its 1.750% Senior Notes due 2030 (together, the "Maximum Tender Offer Notes"). The applicable Reference Yield for the Maximum Tender Offer Notes and the Total Consideration for the Maximum Tender Offer Notes are summarized in the table below: Maximum Tender Offer Notes : Title of Notes CUSIP Number Original Issuer Principal Amount Outstanding Maturity Date Acceptance Priority Level (1) UST Reference Security Bloomberg Reference Page Fixed Spread (bps) Early Tender Payment (2) Reference Yield (3) Total Consideration (2)(3) Approximate Proration Factor (4) 2.700% Senior Notes due 2040 126650DP2 CVS Health Corporation $1,250,000,000 8/21/2040 1 4.625% due 11/15/2044 FIT1 +110 bps $30 4.676 % $685.54 100 % 3.875% Senior Notes due 2047 00817YAZ1 Aetna Inc. $1,000,000,000 8/15/2047 2 4.625% due 11/15/2044 FIT1 +121 bps $30 4.676 % $750.06 100 % 4.250% Senior Notes due 2050 126650DL1 CVS Health Corporation $750,000,000 4/1/2050 3 4.250% due 8/15/2054 FIT1 +136 bps $30 4.611 % $776.80 100 % 4.125% Senior Notes due 2042 00817YAM0 Aetna Inc. $500,000,000 11/15/2042 4 4.625% due 11/15/2044 FIT1 +122 bps $30 4.676 % $805.69 100 % 4.125% Senior Notes due 2040 126650DK3 CVS Health Corporation $1,000,000,000 4/1/2040 5 4.625% due 11/15/2044 FIT1 +119 bps $30 4.676 % $825.77 57.5 % 2.125% Senior Notes due 2031 126650DR8 CVS Health Corporation $1,000,000,000 9/15/2031 6 4.250% due 11/15/2034 FIT1 +92 bps $30 N/A N/A 0 % 1.875% Senior Notes due 2031 126650DQ0 CVS Health Corporation $1,250,000,000 2/28/2031 7 4.250% due 11/15/2034 FIT1 +87 bps $30 N/A N/A 0 % 5.050% Senior Notes due 2048 126650CZ1 CVS Health Corporation $8,000,000,000 3/25/2048 8 4.250% due 8/15/2054 FIT1 +156 bps $30 N/A N/A 0 % 4.500% Senior Notes due 2042 00817YAJ7 Aetna Inc. $500,000,000 5/15/2042 9 4.625% due 11/15/2044 FIT1 +130 bps $30 N/A N/A 0 % 1.750% Senior Notes due 2030 126650DN7 CVS Health Corporation $1,250,000,000 8/21/2030 10 4.125% due 11/30/2029 FIT1 +106 bps $30 N/A N/A 0 % (1) Subject to each of the Maximum Tender Offer Amount and proration, the principal amount of each series of Maximum Tender Offer Notes that is purchased in the Maximum Tender Offer will be determined in accordance with the applicable acceptance priority level (in numerical priority order) specified in this column. (2) Per $1,000 principal amount of Maximum Tender Offer Notes validly tendered at or prior to the Early Tender Date (as defined below) and accepted for purchase. (3) Pricing information has only been provided for the Maximum Tender Offer Notes that are expected to be fully or partially accepted for tender. (4) The proration factor has been rounded to the nearest tenth of a percentage point for presentation purposes. The Maximum Tender Offer is being made upon the terms and subject to the conditions set forth in the Offer to Purchase dated December 2, 2024 (as it may be amended or supplemented from time to time, the "Offer to Purchase"), which sets forth a more detailed description of the Maximum Tender Offer. Copies of the Offer to Purchase are available at www.dfking.com/cvs . The Maximum Tender Offer is open to all registered holders (individually, a "Holder" and collectively, the "Holders") of the Maximum Tender Offer Notes. The Total Consideration payable by CVS Health for the Maximum Tender Offer Notes is a price per $1,000 principal amount calculated as described in the Offer to Purchase in a manner intended to result in a yield to maturity or first par call date, as the case may be, equal to the sum of the yield to maturity of the applicable U.S. Treasury reference security specified in the table above as determined at 10:00 a.m. , New York City time, on December 16, 2024 and the applicable fixed spread shown in the table above. Maximum Tender Offer Notes that were tendered and not validly withdrawn at or prior to 5:00 p.m. , New York City time, on December 13, 2024 (the "Early Tender Date") and that are accepted for purchase will receive the applicable Total Consideration, which includes the Early Tender Payment (as defined in the Offer to Purchase). Maximum Tender Offer Notes that are tendered after the Early Tender Date but at or prior to 5:00 p.m. , New York City time, on December 31, 2024 (the "Maximum Tender Offer Expiration Date") (unless earlier terminated by CVS Health as described in the Offer to Purchase) and that are not validly withdrawn and that are accepted for purchase will receive only the applicable Tender Offer Consideration (as defined in the Offer to Purchase), which is the applicable Total Consideration minus the Early Tender Payment. The Maximum Tender Offer Withdrawal Deadline of 5:00 p.m. , New York City time, on December 13, 2024 has passed and, accordingly, Maximum Tender Offer Notes validly tendered in the Maximum Tender Offer may no longer be withdrawn. The settlement date for the Maximum Tender Offer Notes validly tendered at or prior to the Early Tender Date and accepted for purchase is expected to be December 18, 2024 , the third business day after the Early Tender Date (the "Early Settlement Date"). Although the Maximum Tender Offers is scheduled to expire at 5:00 p.m. , New York City time, on December 31, 2024 , unless extended or terminated, because the aggregate purchase price of Notes validly tendered (and not validly withdrawn) prior to the Early Tender Date exceeded the Maximum Tender Offer Amount, there is not expected to be a Final Settlement Date (as defined in the Offer to Purchase), and no Notes tendered after the Early Tender Date are expected to be accepted for purchase. In addition to the Total Consideration for the Maximum Tender Offer Notes, Holders of the Maximum Tender Offer Notes accepted for purchase on the Early Settlement Date will receive accrued and unpaid interest ("Accrued Interest") on those Maximum Tender Offer Notes from the last interest payment date with respect to those Maximum Tender Offer Notes to, but not including, the Early Settlement Date. CVS Health expressly reserves the right, in its sole discretion, subject to applicable law, to amend, extend or terminate the Maximum Tender Offer with respect to any or all series of Maximum Tender Offer Notes at any time if any condition to the Maximum Tender Offer is not satisfied. The Maximum Tender Offer is not conditioned on any minimum principal amount of Maximum Tender Offer Notes being tendered but the Maximum Tender Offer is subject to certain other general conditions as described in the Offer to Purchase. CVS Health has retained Barclays Capital Inc. and Mizuho Securities USA LLC to act as Dealer Managers for the Maximum Tender Offer. D.F. King & Co., Inc. has been retained to act as the Tender and Information Agent for the Maximum Tender Offer. The Offer to Purchase may be accessed at the following link: http://www.dfking.com/cvs . Requests for assistance relating to the procedures for tendering Maximum Tender Notes may be directed to the Tender and Information Agent either by email at cvs@dfking.com , or by phone (212) 269-5550 (for banks and brokers only) or (800) 487-4870 (for all others toll free). Requests for assistance relating to the terms and conditions of the Maximum Tender Offer may be directed to Barclays Capital Inc. at (800) 438-3242 (toll free) or (212) 528-7581 (collect) or Mizuho Securities USA LLC at (866) 271-7403 (toll-free) or (212) 205-7741. Beneficial owners may also contact their broker, dealer, commercial bank, trust company or other nominee for assistance. This press release does not constitute an offer to sell or purchase, or a solicitation of an offer to sell or purchase, or the solicitation of tenders with respect to, any securities, including the Maximum Tender Offer Notes. No offer, solicitation, purchase or sale will be made in any jurisdiction in which such an offer, solicitation, or sale would be unlawful. The Maximum Tender Offer is being made solely pursuant to the Offer to Purchase made available to Holders of the Maximum Tender Offer Notes. None of CVS Health, the Dealer Managers, Tender and Information Agent or the trustees with respect to the Maximum Tender Offer Notes, or any of their respective affiliates, is making any recommendation as to whether or not Holders should tender or refrain from tendering all or any portion of their Maximum Tender Offer Notes in response to the Maximum Tender Offer. Holders are urged to evaluate carefully all information in the Offer to Purchase, consult their own investment and tax advisers and make their own decisions whether to tender Maximum Tender Offer Notes in the Maximum Tender Offer, and, if so, the principal amount of Maximum Tender Offer Notes to tender. About CVS Health CVS Health is a leading health solutions company building a world of health around every consumer it serves and connecting care so that it works for people wherever they are. As of September 30, 2024 , the Company had more than 9,000 retail locations, more than 900 walk-in medical clinics, more than 225 primary care medical clinics, a leading pharmacy benefits manager with approximately 90 million plan members and expanding specialty pharmacy solutions, and a dedicated senior pharmacy care business serving more than 800,000 patients per year. The Company also serves an estimated more than 36 million people through traditional, voluntary and consumer-directed health insurance products and related services, including expanding Medicare Advantage offerings and a leading standalone Medicare Part D prescription drug plan. The Company is creating new sources of value through its integrated model allowing it to expand into personalized, technology driven care delivery and health services, increasing access to quality care, delivering better health outcomes and lowering overall health care costs. Forward-Looking Statements This press release contains forward-looking statements. The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements made by or on behalf of CVS Health. By their nature, all forward-looking statements are not guarantees of future performance or results and are subject to risks and uncertainties that are difficult to predict and/or quantify. Actual results may differ materially from those contemplated by the forward-looking statements due to the risks and uncertainties described in our Securities and Exchange Commission filings, including those set forth in the Risk Factors section and under the heading "Cautionary Statement Concerning Forward-Looking Statements" in our most recently filed Annual Report on Form 10-K, our Quarterly Reports on Form 10-Q for the quarterly periods ended March 31, 2024 , June 30, 2024 and September 30, 2024 and our Current Reports on Form 8-K. You are cautioned not to place undue reliance on CVS Health's forward-looking statements. CVS Health's forward-looking statements are and will be based upon management's then-current views and assumptions regarding future events and operating performance, and are applicable only as of the dates of such statements. CVS Health does not assume any duty to update or revise forward-looking statements, whether as a result of new information, future events, uncertainties or otherwise. Investor Larry McGrath Media Ethan Slavin Contact: Executive Vice President Contact: 860-273-6095 Chief Strategy Officer & Chief Strategic Advisor to the CEO investorinfo@cvshealth.com Ethan.Slavin@CVSHealth.com View original content to download multimedia: https://www.prnewswire.com/news-releases/cvs-health-corporation-announces-pricing-of-maximum-tender-offer-302333016.html SOURCE CVS Health
Another important aspect of the post-announcement market dynamics is the shift in narrative. The focus has now shifted from doom and gloom to opportunity and growth. Investors are no longer solely concerned with minimizing losses but are actively seeking out opportunities for growth and expansion. This change in mindset is a crucial driver of market sentiment and will likely have a lasting impact on the sector.The situation in Syria has continued to worsen, with increasing clashes between government forces and various opposition groups, leaving civilians caught in the crossfire. The Syrian-Chinese community, a small but tight-knit group, has found themselves particularly vulnerable amidst the chaos and uncertainty.
On the online retail giant Amazon, the price of gold has decreased by 1.5% as compared to last week. The e-commerce platform has also witnessed a decrease in sales of gold products, contributing to the downward pressure on prices.
The semiconductor industry has been experiencing a period of unprecedented growth, driven by trends such as the rapid digitalization of various industries, the rise of 5G technology, the proliferation of Internet of Things (IoT) devices, and the increasing adoption of artificial intelligence and machine learning technologies. As a leading semiconductor manufacturer, TSMC has been at the forefront of this growth, providing advanced semiconductor solutions that power a wide range of applications and devices.